These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 8040130)

  • 21. ESGAB breakpoint determination: temafloxacin.
    Phillips I; Acar J; Baquero F; Bergan T; Forsgren A; Wiedemann B
    Eur J Clin Microbiol Infect Dis; 1991 Nov; 10(11):991-2. PubMed ID: 1665417
    [No Abstract]   [Full Text] [Related]  

  • 22. Is Escherichia coli ATCC 25922 useful for monitoring broth microdilution tests of fluoroquinolones?
    Fuchs PC; Barry AL; Brown SD
    J Antimicrob Chemother; 1997 Apr; 39(4):549-50. PubMed ID: 9145831
    [No Abstract]   [Full Text] [Related]  

  • 23. Susceptibility of recent clinical isolates to temafloxacin (A-63004) and other antimicrobial agents.
    Qadri SM; Ueno Y; Burns JJ; Almodovar E; Rabea N
    Drugs Exp Clin Res; 1992; 18(8):311-7. PubMed ID: 1338041
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro evaluation of lomefloxacin (NY-198 or SC-47111), a new difluoro-quinolone.
    Jones RN
    J Chemother; 1989 Jul; 1(4 Suppl):165-7. PubMed ID: 16312353
    [No Abstract]   [Full Text] [Related]  

  • 25. Cross-resistance analysis for clinafloxacin compared with ciprofloxacin, fleroxacin, ofloxacin, and sparfloxacin using a predictor panel of ciprofloxacin-resistant bacteria.
    Cormican MG; Jones RN
    J Antimicrob Chemother; 1995 Aug; 36(2):431-4. PubMed ID: 8522474
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibacterial activities of grepafloxacin, ciprofloxacin, ofloxacin and fleroxacin.
    Barry AL; Fuchs PC
    J Chemother; 1997 Feb; 9(1):9-16. PubMed ID: 9106012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In-vitro comparison of DU-6859a, a novel fluoroquinolone, with other quinolones and oral cephalosporins tested against 5086 recent clinical isolates.
    Marshall SA; Jones RN; Murray PR; Washington JA; Allen SD; Gerlach EH; Erwin ME
    J Antimicrob Chemother; 1993 Dec; 32(6):877-84. PubMed ID: 8144428
    [No Abstract]   [Full Text] [Related]  

  • 28. In vitro activity of sparfloxacin against selected gram-negative blood culture isolates.
    Siristonpun Y; Rojnpisarnvong V; Chongchitmate A; Srimuang S; Tanphaichitra D
    Drugs; 1995; 49 Suppl 2():256. PubMed ID: 8549322
    [No Abstract]   [Full Text] [Related]  

  • 29. In-vitro activity of a new quinolone, clinafloxacin, against clinical isolates of Corynebacterium species.
    Yagüe G; Herrera EA; Segovia M
    J Antimicrob Chemother; 1996 Oct; 38(4):740-2. PubMed ID: 8937971
    [No Abstract]   [Full Text] [Related]  

  • 30. In-vitro and in-vivo activities of DW-116, a new fluoroquinolone.
    Choi KH; Hong JS; Kim SK; Lee DK; Yoon SJ; Choi EC
    J Antimicrob Chemother; 1997 Apr; 39(4):509-14. PubMed ID: 9145824
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The in-vitro activity of tosufloxacin, a new fluorinated quinolone, compared with that of ciprofloxacin and temafloxacin.
    King A; Bethune L; Phillips I
    J Antimicrob Chemother; 1991 Nov; 28(5):719-25. PubMed ID: 1663930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones.
    Wise R; Brenwald NP; Andrews JM; Boswell F
    J Antimicrob Chemother; 1997 Apr; 39(4):447-52. PubMed ID: 9145816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In-vitro activities of temafloxacin, tosufloxacin (A-61827) and five other fluoroquinolone agents.
    Barry AL; Jones RN
    J Antimicrob Chemother; 1989 Apr; 23(4):527-35. PubMed ID: 2745259
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunomodulating activity of DW-116, a new quinolone antibiotic.
    Moon EY; Choi CH; Pyo S; Chung YH; Yoon SJ; Lee DK
    Arch Pharm Res; 1998 Oct; 21(5):610-4. PubMed ID: 9875503
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The in-vitro activity of temafloxacin compared with other antimicrobial agents.
    King A; Bethune L; Phillips I
    J Antimicrob Chemother; 1991 Jun; 27(6):769-79. PubMed ID: 1657855
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro susceptibility of anaerobic bacteria to temafloxacin.
    Southern PM; Patel S
    Clin Infect Dis; 1993 Jun; 16 Suppl 4():S334. PubMed ID: 8391861
    [No Abstract]   [Full Text] [Related]  

  • 37. [In vitro antibacterial activity of prulifloxacin, a new oral quinolone, and comparative susceptibility rate at clinical breakpoint MIC].
    Inoue M; Kuga A; Kaieda S; Hosaka M; Kitasato H; Sato Y; Okamoto R; Eda T; Hoshino K; Seto I
    Jpn J Antibiot; 2000 Sep; 53(9):593-608. PubMed ID: 11214999
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of in vitro antimicrobial activity of AM-1155 with those of tosufloxacin and fleroxacin against clinical isolates of Neisseria gonorrhoeae harboring quinolone resistance alterations in GyrA and ParC.
    Deguchi T; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Fukuda H; Maeda S; Saito I; Kawada Y
    Chemotherapy; 1997; 43(4):239-44. PubMed ID: 9209780
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro susceptibility to ciprofloxacin of bacterial strains isolated from chronic otitis media and chronic sinusitis.
    Gaillot O; Berche P
    Drugs; 1995; 49 Suppl 2():200-2. PubMed ID: 8549303
    [No Abstract]   [Full Text] [Related]  

  • 40. In-vitro activity of PD 117558, a new quinolone against bacterial isolates from cancer patients.
    Rolston KV; LeBlanc B; Gooch G; Ho DH; Bodey GP
    J Antimicrob Chemother; 1989 Mar; 23(3):363-71. PubMed ID: 2732120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.